title: Expanding public-private collaborations to enhance cancer drug development: a report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century".
abstract: Since their inception in the 1950s, the National Cancer Institute-funded cancer cooperative groups have been important contributors to cancer clinical and translational research. In 2010, a committee appointed by the Institute of Medicine (IOM) of the National Academy of Sciences completed a consensus review on the status of the U.S. publicly funded cancer clinical trials system. This report identified a need to reinvigorate the cooperative groups and provided recommendations for improving their effectiveness. Follow-up workshops to monitor progress were conducted by the IOM's National Cancer Policy Forum and the American Society of Clinical Oncology (ASCO) in 2011 and 2013. One of the key recommendations of the IOM report was a call for greater collaboration among stakeholders in cancer research. In particular, more active engagement and better alignment of incentives among the cooperative groups, the National Cancer Institute, the U.S. Food and Drug Administration, and the biopharmaceutical industry were identified as essential to achieving the promise of oncology drug development. This review, based on presentations and discussion during the IOM-ASCO workshops, outlines the progress and remaining challenges of these collaborations.
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA mbertagnolli@partners.org.
authors.forename: Monica M
authors.initials: MM
authors.lastname: Bertagnolli
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA.
authors.forename: Renzo
authors.initials: R
authors.lastname: Canetta
authors.affiliation: Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA; Bristol-Myers Squibb, Wallingford, Connecticut, USA; National Cancer Policy Forum, Institute of Medicine of the National Academies, Washington, D.C., USA.
authors.forename: Sharyl J
authors.initials: SJ
authors.lastname: Nass
mesh_terms: D000970:Antineoplastic Agents; D035843:Biomedical Research / Q000458:organization & administration* / Q000639:trends; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000458:organization & administration*; D006801:Humans; D054547:National Cancer Institute (U.S.); D055818:Public-Private Sector Partnerships / Q000458:organization & administration*; D012958:Societies, Scientific; D057170:Translational Research, Biomedical / Q000458:organization & administration / Q000639:trends; D014481:United States
chemical_list: D000970:Antineoplastic Agents
keywords: Clinical trials; Drug development; Institute of Medicine; National Cancer Institute